You are here

  • Home
  • Archive
  • Volume 15, Issue 5
  • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Citation Tools

Article menu
Download PDFPDF
Original Article
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
GORDON AN, FINKLER N, EDWARDS RP, et al
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
International Journal of Gynecologic Cancer 2005;15:785-792.